Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study

Inclusion Criteria: * Patients of both sexes aged 18 to 75 years, who are citizens of the Republic of Kazakhstan; * Patients with a clinically and laboratory confirmed diagnosis of MAFLD, without severe concomitant diseases; * Patients who do not receive other adjuvant therapy (metabolic therapy drugs, essential phospholipids, ursodeoxycholic acid, glycyrrhizic acid, ademetionine and others); * Patients who have at least a 7-day gap between the end of other adjuvant therapy and the start of COC and BDD; * Patients who voluntarily signed the informed consent form. Exclusion Criteria: * Patients who abuse alcohol according to the AUDIT-c questionnaire; * Patients taking COC for more than 4 weeks before signing the informed consent; * Patients with contraindications to COC; * Patients diagnosed with diabetes mellitus; * Pregnancy and lactation; * Simultaneous use of levodopa, altretamine, cisplatin, statins; * Patients with coinfection with HIV, HBV, HCV; * Decompensated liver cirrhosis CPT≥7 points; * GFR ≤ 15 ml/min/1.73 m2; * Drug-induced liver damage; * Taking narcotic and psychotropic drugs; * Malignant formations of the liver and other organs (in history and currently) or a clinically significant increase in alpha-fetoprotein more than \>5 times; * patients with pronounced biochemical activity (ALT, AST more than 10 ULN) and total bilirubin more than 2 ULN; * Participation in an interventional clinical trial.